$0.03
7.41% day before yesterday
Nasdaq, Nov 14, 03:30 pm CET
ISIN
US39868T1051
Symbol
GRTS
Sector
Industry

Gritstone Oncology, Inc. Stock price

$0.02
-0.05 66.33% 1M
-0.73 96.92% 6M
-2.02 98.87% YTD
-1.42 98.40% 1Y
-11.22 99.79% 3Y
-7.32 99.69% 5Y
-14.22 99.84% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.00 7.60%
ISIN
US39868T1051
Symbol
GRTS
Sector
Industry

Key metrics

Market capitalization $2.73m
Enterprise Value $48.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 96.46
P/S ratio (TTM) P/S ratio 5.46
P/B ratio (TTM) P/B ratio 0.12
Revenue growth (TTM) Revenue growth -81.66%
Revenue (TTM) Revenue $500.00k
EBIT (operating result TTM) EBIT $-150.58m
Free Cash Flow (TTM) Free Cash Flow $-112.43m
Cash position $56.99m
EPS (TTM) EPS $-1.15
P/E forward negative
P/S forward 1.09
EV/Sales forward 17.94
Short interest 6.51%
Show more

Is Gritstone Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Gritstone Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Gritstone Oncology, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Gritstone Oncology, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Gritstone Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.50 0.50
82% 82%
100%
- Direct Costs 7.23 7.23
61% 61%
1,446%
-6.73 -6.73
57% 57%
-1,346%
- Selling and Administrative Expenses 17 17
268% 268%
3,414%
- Research and Development Expense 120 120
2% 2%
23,910%
-143 -143
17% 17%
-28,670%
- Depreciation and Amortization 7.23 7.23
61% 61%
1,446%
EBIT (Operating Income) EBIT -151 -151
7% 7%
-30,116%
Net Profit -133 -133
2% 2%
-26,606%

In millions USD.

Don't miss a Thing! We will send you all news about Gritstone Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gritstone Oncology, Inc. Stock News

Neutral
Business Wire
about one month ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the ...
Neutral
GlobeNewsWire
about 2 months ago
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly
Neutral
GlobeNewsWire
3 months ago
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in...
More Gritstone Oncology, Inc. News

Company Profile

Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Head office United States
CEO Andrew Allen
Employees 231
Founded 2015
Website www.gritstonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today